Literature DB >> 29664014

RIP kinase 1-dependent endothelial necroptosis underlies systemic inflammatory response syndrome.

Matija Zelic1, Justine E Roderick1, Joanne A O'Donnell1, Jesse Lehman1, Sung Eun Lim1, Harish P Janardhan2, Chinmay M Trivedi2, Manolis Pasparakis3, Michelle A Kelliher1.   

Abstract

Receptor interacting protein kinase 1 (RIPK1) has important kinase-dependent and kinase-independent scaffolding functions that activate or prevent apoptosis or necroptosis in a cell context-dependent manner. The kinase activity of RIPK1 mediates hypothermia and lethality in a mouse model of TNF-induced shock, reflecting the hyperinflammatory state of systemic inflammatory response syndrome (SIRS), where the proinflammatory "cytokine storm" has long been viewed as detrimental. Here, we demonstrate that cytokine and chemokine levels did not predict survival and, importantly, that kinase-inactive Ripk1D138N/D138N hematopoietic cells afforded little protection from TNF- or TNF/zVAD-induced shock in reconstituted mice. Unexpectedly, RIPK1 kinase-inactive mice transplanted with WT hematopoietic cells remained resistant to TNF-induced shock, revealing that a nonhematopoietic lineage mediated protection. TNF-treated Ripk1D138N/D138N mice exhibited no significant increases in intestinal or vascular permeability, nor did they activate the clotting cascade. We show that TNF administration damaged the liver vascular endothelium and induced phosphorylated mixed lineage kinase domain-like (phospho-MLKL) reactivity in endothelial cells isolated from TNF/zVAD-treated WT, but not Ripk1D138N/D138N, mice. These data reveal that the tissue damage present in this SIRS model is reflected, in part, by breaks in the vasculature due to endothelial cell necroptosis and thereby predict that RIPK1 kinase inhibitors may provide clinical benefit to shock and/or sepsis patients.

Entities:  

Keywords:  Coagulation; Cytokines; Immunology; Inflammation; endothelial cells

Mesh:

Substances:

Year:  2018        PMID: 29664014      PMCID: PMC5919800          DOI: 10.1172/JCI96147

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Liver-resident macrophage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue repair during bacterial infection.

Authors:  Camille Blériot; Théo Dupuis; Grégory Jouvion; Gérard Eberl; Olivier Disson; Marc Lecuit
Journal:  Immunity       Date:  2014-12-25       Impact factor: 31.745

2.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

3.  RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis.

Authors:  Marius Dannappel; Katerina Vlantis; Snehlata Kumari; Apostolos Polykratis; Chun Kim; Laurens Wachsmuth; Christina Eftychi; Juan Lin; Teresa Corona; Nicole Hermance; Matija Zelic; Petra Kirsch; Marijana Basic; Andre Bleich; Michelle Kelliher; Manolis Pasparakis
Journal:  Nature       Date:  2014-08-17       Impact factor: 49.962

4.  RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3.

Authors:  Christopher P Dillon; Ricardo Weinlich; Diego A Rodriguez; James G Cripps; Giovanni Quarato; Prajwal Gurung; Katherine C Verbist; Taylor L Brewer; Fabien Llambi; Yi-Nan Gong; Laura J Janke; Michelle A Kelliher; Thirumala-Devi Kanneganti; Douglas R Green
Journal:  Cell       Date:  2014-05-08       Impact factor: 41.582

5.  Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.

Authors:  Kim Newton; Debra L Dugger; Katherine E Wickliffe; Neeraj Kapoor; M Cristina de Almagro; Domagoj Vucic; Laszlo Komuves; Ronald E Ferrando; Dorothy M French; Joshua Webster; Merone Roose-Girma; Søren Warming; Vishva M Dixit
Journal:  Science       Date:  2014-02-20       Impact factor: 47.728

6.  Genome-wide comparison between IL-17 and combined TNF-alpha/IL-17 induced genes in primary murine hepatocytes.

Authors:  Titus Sparna; Julia Rétey; Kathrin Schmich; Ute Albrecht; Katrin Naumann; Norbert Gretz; Hans-Peter Fischer; Johannes G Bode; Irmgard Merfort
Journal:  BMC Genomics       Date:  2010-04-07       Impact factor: 3.969

7.  Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4.

Authors:  Kim Newton; Xiaoqing Sun; Vishva M Dixit
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

8.  RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition.

Authors:  William J Kaiser; Lisa P Daley-Bauer; Roshan J Thapa; Pratyusha Mandal; Scott B Berger; Chunzi Huang; Aarthi Sundararajan; Hongyan Guo; Linda Roback; Samuel H Speck; John Bertin; Peter J Gough; Siddharth Balachandran; Edward S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

9.  Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice.

Authors:  Scott B Berger; Viera Kasparcova; Sandy Hoffman; Barb Swift; Lauren Dare; Michelle Schaeffer; Carol Capriotti; Michael Cook; Joshua Finger; Angela Hughes-Earle; Philip A Harris; William J Kaiser; Edward S Mocarski; John Bertin; Peter J Gough
Journal:  J Immunol       Date:  2014-05-12       Impact factor: 5.422

Review 10.  An evolving new paradigm: endothelial cells--conditional innate immune cells.

Authors:  Jietang Mai; Anthony Virtue; Jerry Shen; Hong Wang; Xiao-Feng Yang
Journal:  J Hematol Oncol       Date:  2013-08-22       Impact factor: 17.388

View more
  25 in total

1.  miR-425-5p improves inflammation and septic liver damage through negatively regulating the RIP1-mediated necroptosis.

Authors:  Changwei Gu; Chongzhi Hou; Sheng Zhang
Journal:  Inflamm Res       Date:  2020-01-30       Impact factor: 4.575

Review 2.  Cell death of intestinal epithelial cells in intestinal diseases.

Authors:  Saravanan Subramanian; Hua Geng; Xiao-Di Tan
Journal:  Sheng Li Xue Bao       Date:  2020-06-25

Review 3.  Necroptosis: a crucial pathogenic mediator of human disease.

Authors:  Mary E Choi; David R Price; Stefan W Ryter; Augustine M K Choi
Journal:  JCI Insight       Date:  2019-08-08

4.  Mixed lineage kinase domain-like pseudokinase-mediated necroptosis aggravates periodontitis progression.

Authors:  Yanan Yang; Lingxia Wang; Haibing Zhang; Lijun Luo
Journal:  J Mol Med (Berl)       Date:  2021-10-13       Impact factor: 4.599

5.  RIPK3 collaborates with GSDMD to drive tissue injury in lethal polymicrobial sepsis.

Authors:  Hui Chen; Yinshuang Li; Jianfeng Wu; Guoping Li; Xuan Tao; Kunmei Lai; Ying Yuan; Xiaohong Zhang; Zhenhuan Zou; Yanfang Xu
Journal:  Cell Death Differ       Date:  2020-03-09       Impact factor: 15.828

6.  Mitofusin-2 stabilizes adherens junctions and suppresses endothelial inflammation via modulation of β-catenin signaling.

Authors:  Young-Mee Kim; Sarah Krantz; Ankit Jambusaria; Peter T Toth; Hyung-Geun Moon; Isuru Gunarathna; Gye Young Park; Jalees Rehman
Journal:  Nat Commun       Date:  2021-05-12       Impact factor: 14.919

7.  Genetic inactivation of RIP1 kinase does not ameliorate disease in a mouse model of ALS.

Authors:  Sara Dominguez; Eugene Varfolomeev; Robert Brendza; Kim Stark; Joy Tea; Jose Imperio; Hai Ngu; Timothy Earr; Oded Foreman; Joshua D Webster; Amy Easton; Domagoj Vucic; Baris Bingol
Journal:  Cell Death Differ       Date:  2020-09-29       Impact factor: 15.828

8.  Graft-versus-host disease propagation depends on increased intestinal epithelial tight junction permeability.

Authors:  Sam C Nalle; Li Zuo; Ma Lora Drizella M Ong; Gurminder Singh; Alicia M Worthylake; Wangsun Choi; Mario Cabrero Manresa; Anna P Southworth; Karen L Edelblum; Gregory J Baker; Nora E Joseph; Peter A Savage; Jerrold R Turner
Journal:  J Clin Invest       Date:  2019-01-22       Impact factor: 19.456

9.  Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.

Authors:  Lauren Mifflin; Dimitry Ofengeim; Junying Yuan
Journal:  Nat Rev Drug Discov       Date:  2020-07-15       Impact factor: 112.288

10.  RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.

Authors:  Henry G Smith; Kunzah Jamal; Kevin J Harrington; Pascal Meier; Jasbani Hs Dayal; Tencho Tenev; Joan Kyula-Currie; Naomi Guppy; Patrycja Gazinska; Victoria Roulstone; Gianmaria Liccardi; Emma Davies; Ioannis Roxanis; Alan A Melcher; Andrew J Hayes; Gareth J Inman
Journal:  EMBO Mol Med       Date:  2020-05-18       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.